Director Dealing

RNS Number : 5055D
Arecor Therapeutics PLC
29 June 2021
 

Arecor Therapeutics plc

 

("Arecor", the "Company" or the "Group")

 

Director Dealing

 

Cambridge, UK, 29th June 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Susan Lowther, Chief Financial Officer, has purchased 12,515 ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") at a price of 235 pence per Ordinary Share.

 

Following the transaction, the total beneficial interest of Susan Lowther is 110,681 Ordinary Shares, representing 0.40% of the total voting rights.

 

-ENDS-

 

 

For more information, please contact:

Arecor Therapeutics plc

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

 

 

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

 

 

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com

 

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

 

 

 

Consilium Strategic Communications

 

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market.  Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.  Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

 

For further details please see our website, www.arecor.com

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

  1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Susan Lowther

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Arecor Therapeutics plc

b)

LEI

98450093D12I3A8DDD58

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares

b)

Identification Code

GB00BMWLM973

c)

Nature of the transaction

Purchase of shares




d)

Price(s) and volume(s)

 235 pence and 12,515 Ordinary Shares

e)

Aggregated information

- Aggregated volume

- Aggregated price

N/A

f)

Date of the transaction

29 June 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZGZVMLFGMZM
UK 100

Latest directors dealings